Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers

Platinum-based combination therapy is the standard first-line treatment for women with advanced serous epithelial ovarian carcinoma (EOC). However, about 20 % will not respond and are considered clinically resistant. The availability of biomarkers to predict responses to the initial therapy would pr...

Full description

Saved in:
Bibliographic Details
Published in:BMC cancer 2015-07, Vol.15 (1), p.492-492, Article 492
Main Authors: Lane, Denis, Matte, Isabelle, Garde-Granger, Perrine, Laplante, Claude, Carignan, Alex, Rancourt, Claudine, Piché, Alain
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Analysis
Apoptosis
Ascites
Ascites - metabolism
Ascites - pathology
Ascitic Fluid - metabolism
Biological markers
Biomarkers
Biomarkers, Tumor - genetics
CA-125 Antigen - genetics
Cancer therapies
Carcinoma, Ovarian Epithelial
Care and treatment
Chemotherapy
Cystadenocarcinoma, Serous - drug therapy
Cystadenocarcinoma, Serous - genetics
Cystadenocarcinoma, Serous - pathology
Cytokines
Development and progression
Diagnosis, Differential
Disease
Disease-Free Survival
Drug resistance
Drug Resistance, Neoplasm - genetics
Female
Growth factors
Gynecology
Health aspects
Humans
Inflammation
Interleukin-6 - genetics
Leptin
Medical prognosis
Membrane Proteins - genetics
Middle Aged
Neoplasms, Glandular and Epithelial - drug therapy
Neoplasms, Glandular and Epithelial - genetics
Neoplasms, Glandular and Epithelial - pathology
Ovarian cancer
Ovarian Neoplasms - drug therapy
Ovarian Neoplasms - genetics
Ovarian Neoplasms - pathology
Patients
Surgery
Tumor Microenvironment - genetics
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Platinum-based combination therapy is the standard first-line treatment for women with advanced serous epithelial ovarian carcinoma (EOC). However, about 20 % will not respond and are considered clinically resistant. The availability of biomarkers to predict responses to the initial therapy would provide a practical approach to identify women who would benefit from a more appropriate first-line treatment. Ascites is an attractive inflammatory fluid for biomarker discovery as it is easy and minimally invasive to obtain. The aim of this study was to evaluate whether six selected inflammation-regulating factors in ascites could serve as diagnostic or drug resistance biomarkers in patients with advanced serous EOC. A total of 53 women with stage III/IV serous EOC and 10 women with benign conditions were enrolled in this study. Eleven of the 53 women with serous EOC were considered clinically resistant to treatment with progression-free survival
ISSN:1471-2407
1471-2407
DOI:10.1186/s12885-015-1511-7